128 related articles for article (PubMed ID: 20876805)
1. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.
Rossi EA; Rossi DL; Stein R; Goldenberg DM; Chang CH
Cancer Res; 2010 Oct; 70(19):7600-9. PubMed ID: 20876805
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.
Rossi EA; Rossi DL; Cardillo TM; Stein R; Goldenberg DM; Chang CH
Blood; 2011 Aug; 118(7):1877-84. PubMed ID: 21680794
[TBL] [Abstract][Full Text] [Related]
3. A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.
Zeng J; Liu R; Wang J; Fang Y
J Cancer Res Clin Oncol; 2015 Nov; 141(11):1899-907. PubMed ID: 25773122
[TBL] [Abstract][Full Text] [Related]
4. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.
Zhao L; Xie F; Tong X; Li H; Chen Y; Qian W; Duan S; Zheng J; Zhao Z; Li B; Zhang D; Zhao J; Dai J; Wang H; Hou S; Guo Y
MAbs; 2014; 6(3):740-8. PubMed ID: 24670986
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
[TBL] [Abstract][Full Text] [Related]
6. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.
Piccione EC; Juarez S; Liu J; Tseng S; Ryan CE; Narayanan C; Wang L; Weiskopf K; Majeti R
MAbs; 2015; 7(5):946-56. PubMed ID: 26083076
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
8. Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
Li B; Zhang X; Shi S; Zhao L; Zhang D; Qian W; Zheng L; Gao J; Wang H; Guo Y
Cancer Res; 2010 Aug; 70(15):6293-302. PubMed ID: 20631068
[TBL] [Abstract][Full Text] [Related]
9. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
10. A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies.
Brard PY; Karacay H; Stein R; Sharkey RM; Mattes MJ; Chang CH; Rossi EA; McBride WJ; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5564s-5571s. PubMed ID: 17875790
[TBL] [Abstract][Full Text] [Related]
11. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
12. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
13. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Wang Y; Chang CH
Cancer Res; 2008 Oct; 68(20):8384-92. PubMed ID: 18922911
[TBL] [Abstract][Full Text] [Related]
14. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
[TBL] [Abstract][Full Text] [Related]
15. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
DeNardo GL; Tobin E; Chan K; Bradt BM; DeNardo SJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7075s-7079s. PubMed ID: 16203805
[TBL] [Abstract][Full Text] [Related]
16. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.
Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Chang CH
Blood; 2009 Jun; 113(24):6161-71. PubMed ID: 19372261
[TBL] [Abstract][Full Text] [Related]
17. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
18. Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP.
Zhao L; Tong Q; Qian W; Li B; Zhang D; Fu T; Duan S; Zhang X; Zhao J; Dai J; Wang H; Hou S; Guo Y
Blood; 2013 Dec; 122(26):4230-6. PubMed ID: 24178967
[TBL] [Abstract][Full Text] [Related]
19. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
van der Kolk LE; de Haas M; Grillo-López AJ; Baars JW; van Oers MH
Leukemia; 2002 Apr; 16(4):693-9. PubMed ID: 11960351
[TBL] [Abstract][Full Text] [Related]
20. IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.
Cardillo TM; Govindan SV; Zalath MB; Rossi DL; Wang Y; Chang CH; Goldenberg DM
Mol Cancer Ther; 2018 Jan; 17(1):150-160. PubMed ID: 29133623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
